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Reconstruction of the bladder urothelium requires human bladder epithelial cells (hBECs), 
which are known to have an inconsistent recovery and growth rate following cryopreservation. 
This study aims to determine methods to increase recovery and rates of proliferation after 
cryopreservation. Specifically, our study looks to improve upon the current existing protocol of 
cryopreserving hBECs which allow for limited recovery and slow growth. Based on a review of 
prior literature, experiments were divided into two categories. One group of experiments focused 
primarily on the determining the optimal chemical composition of the freezing mixture by which 
hBECs were treated with prior to freezing, while maintaining physical parameters such as the 
cooling rate, cell density, and equilibration time. The other group of experiments focused on 
altering the above physical parameters that the cells were exposed to while maintaining a 
consistent freezing mixture consisting of DMSO and hBEC culturing medium. Analysis of the data 
demonstrated that cells treated with 10% DMSO and 10% PEG each had fairly high recoveries, 
and mixtures of the two resulted in consistent, and slightly higher recoveries. When ROCK 
inhibitor or PVA was added into the 10% DMSO freezing mixture, it was found that there were 
optimal concentrations of ROCK inhibitor and PVA resulted in significant increases in growth 
when added to the freezing mixture. In terms of physical parameters, increases in exposure to 
penetrating CPAs at room temperature resulted in decreases in recovery. Based on these results, 
alteration or addition of either of these factors allows for the increase in hBEC recovery following 
cryopreservation. Further research is needed to investigate the effects of cryopreservation on 
urothelial marker expression as well as clinical applications of cryopreserved hBECs in the 
reconstructive process of the urothelium. 
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Chapter 1: Introduction 
Bladder cancer is currently the ninth most common cancer globally, and in the United 
States, it is now the fourth most common cancer in men1. Currently, bladder cancer is treated 
through a radical cystectomy, in which the entire bladder is removed. The most common treatment 
is the ileal conduit, in which a section of the small intestine takes the place of the bladder, as a 
reservoir for urine. While this procedure is currently the gold standard, there are many problems 
with incontinence as well as a reduced bladder volume2–4. However, recent advances in tissue 
engineering allow for the possible reconstruction of the bladder, one that may be functional and 
serve as a better alternative5.  
In order to artificially reconstruct the urothelial layer of a bladder, human bladder epithelial 
cells (hBECs) are ideally used in the place of urothelial cells. It has been previously reported that 
hBECs have a very slow proliferation time, a limited number of passages, and low viability after 
using conventional methods of cryopreservation. As a result, because of the inconsistency that 
occurs, there is typically an insufficient quantity of hBECs that allow for growth of the bladder; in 
addition, inconsistent growth and storage makes the possibility of a reconstructed functional 
bladder far less of a possibility. Because of this occurrence, we researched methods improve their 
viability after freezing, as well as to increase their rate of growth after being seeded in culture flaks 
with the use of cryoprotective agents and other substances reported in literature. Cryoprotective 
agents (CPAs) generally protect cells from injury during freezing, but have differ among 
themselves in their cryoprotective effects. In addition, there a number of factors outside of the 
immediate addition of CPAs that can influence the viability and proliferation of cells. To test these 
factors, we observe the effects of different CPAs on viability and proliferation, and then selected 
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the best penetrating CPA and non-penetrating CPA in the combinatory effects. After observing the 
best performing CPA mixture, we tested equilibration times, addition of ice recrystallization 
inhibitors (IRIs), storage times, cell density, and cooling rates. With these experiments, we were 
able to successfully determine the optimal conditions by which the hBECs were to be frozen. We 
believe that this method will be the foreground for which hBECs will be cryopreserved in the 
future, as well as to provide insight into the factors that have the most influence on 
cryopreservation of cells in general.  
Chapter 2: Background 
To understand the scope of our work, it is important to know the foundational concepts 
behind the methods. It is important to know the properties of hBECs and why there is a need for 
optimization, as well as understanding the mechanics of freezing using DMSO and other 
cryoprotective agents. 
2.1 Human bladder epithelial cells and the bladder 
The bladder is a unique organ in the urinary tract that serves as the reservoir for urine that 
is composed of three components major components: the detrusor muscle, the submucosa, and the 
urothelium6. In order to reconstruct a bladder, the submucosa and urothelium must be taken into 
account. The submucosa, which contains the stroma, can be developed using cells with similar 
properties that can be seeded on a scaffold.  However, in order to construct the urothelium, human 
bladder epithelial cells are required on the luminal side of the scaffold7. hBECs are therefore are 
important in their use as models for the development of diagnostic methods, or for studying 
epithelial development and function8,9. However, hBECs grow very slowly, reaching 90% 
confluency in 10 days, compared to other mammalian cell lines that become confluent after a few 
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days. Despite the growing interest in using hBECs in research, cryopreservation and proliferation 
is consistently a problem. There are few reports on the cryopreservation of bladder epithelial cells, 
in which hBECs were frozen using a conventional freezing method, by using DMSO in cell 
medium. No further studies have been performed regarding the cryopreservation of bladder cells, 
as well as regarding the rate of proliferation and viability of the cells following cryopreservation.   
2.2 Mechanisms of freezing 
During the freezing process, the expansion of water into ice results in two types of injury, 
due to ice being a relatively pure substance, resulting in an increasingly concentrated solution from 
the reduced solvent. If cooling proceeds slowly, ice formation occurs extracellularly, causing the 
cell to lose water due to the osmotic gradient, and the excessive loss of water could result in 
osmotic injury. If cooling proceeds more rapidly, water has less time to leave the cell and freezing 
occurs intracellularly, resulting in mechanical stress on the cell membrane. Because of these two 
different types of injuries, there exists an optimal cooling rate at which both of these effects are 
minimized.  
An alternative method of cryopreservation, known as vitrification, typically involves 
hydrated living cells to be cryopreserved in the absence of ice. Vitrification has recently become 
popular because it eliminates mechanical injury from ice, the need to find an optimal cooling rate, 
as well as the need to find the balance between intracellular ice formation and solute effects. 
However, vitrification almost always requires a high CPA concentration10,11.  
2.3 Cryoprotective Agents 
Cryoprotective agents (CPAs) are divided into two classes: penetrating and non-
penetrating. Penetrating CPAs (pCPAs) include dimethyl sulfoxide (DMSO), glycerol, ethylene 
glycol, and propylene glycol, and are typically the commonly used type of CPA during 
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cryopreservation. They tend to be small, uncharged particles that penetrate the cell membrane in 
order to prevent intracellular ice crystal formation and dehydration by creating an environment 
that allows for the reduction of water within the cell. Because of their size, they are typically able 
to form hydrogen bonds with water to prevent ice crystallization and can control cell size changes. 
Non-penetrating CPAs (npCPAs) tend to be larger molecules such as poly(ethylene glycol) 
or saccharides that do not pass through the cell membrane. They act by dehydrating the cell prior 
to freezing, reducing the amount of water that is lost in order to offset the osmotic imbalance 
caused by freezing. npCPAs also prevent damage to cells during recovery after cryopreservation 
by preventing a loss of necessary solutes from escaping the cell too rapidly. in addition, when 
paired with their penetrating counterparts, npCPAs can reduce the cell volume and increase 
intracellular osmolarity, further preventing intracellular ice formation10. To further investigate 
these cryoprotective effects on hBECs, we investigated a number of different CPAs based on prior 
research and applied Mazur’s two-factor hypothesis, which posits that freezing is based on altered 
solution properties and intracellular freezing. Consideration of these two factors creates the 
potential for optimized conditions that minimizes both of these otherwise detrimental effects12–14. 
Dimethyl sulfoxide (DMSO), a penetrating CPA, has been the standard CPA for cell 
cryopreservation; however, it is highly toxic as it interferes with cell membranes and has 
potentially harmful effects in clinical applications15. Prior research has found that a combination 
of npCPAs can result in comparable, and sometimes, even higher recovery16. One study evaluated 
the cryopreservation of neonatal thymus tissue and stromal epithelial cells using various 
combinations of pCPAs and npCPAs together; it was found that a mixture of 95% dextran-40 and 
5% DMSO provided the best cryopreservative capabilities in terms of viability and functionality17.  
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2.4 Mazur 2-factor hypothesis 
Chinese hamster tissue-cells were frozen at 0.4 M solutions of sucrose, DMSO, and 
glycerol. Cells that were frozen at a rate faster than the optimal freezing rate were more sensitive 
to slow arming, and it was found that the temperatures at which cells were killed were significantly 
different based on the rate at which they were frozen. Therefore, the Mazur 2-factor hypothesis 
postulates that freezing is based on two factors: altered solution properties in the extracellular and 
intracellular solution as well as the formation of intracellular ice. Consideration of these two 
factors during cryopreservation creates the potential for optimized conditions that minimizes the 
effects of both intracellular freezing and solute effects12. 
2.5 ROCK Inhibitor 
Rho-associated coiled coil kinase (ROCK) proteins are typically associated with a range of 
cellular functions involving actin cytoskeleton reorganization, which includes cell adhesion, 
cytokinesis, and apoptosis. While the exact mechanism of ROCK inhibitor of Recently, ROCK 
inhibitor has been thoroughly investigated in the cryopreservation process of stem cells. Previous 
reports have shown that incorporation of 10 μM of ROCK inhibitor into the culture medium 24 
hours after thawing resulted in higher proliferation as well as showing signs of differentiation18,19. 
More recently, another study researched the incorporation of ROCK inhibitor in both the culturing 
medium and the freezing medium; it was found that the incorporation of ROCK inhibitor freezing 
medium aided in the recovery as well20.  
2.6 Ice recrystallization inhibitors 
A new type of cryoprotective agent, known as an ice recrystallization inhibitor (IRI), has 
been recently implemented in the cryopreservation process. IRIs are molecules that prevent or 
reduces ice nucleation and growth, specifically by adsorbing to the surface of ice crystals and 
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preventing them from growing despite the cooling temperature. Natural ice blockers include 
antifreeze proteins, or AFPs, which occur naturally in some Antarctic fish; however, ice blockers 
are typically thought of as synthetic chemicals, such as polyvinyl alcohol (PVA) 10,21–23. It has been 
previously researched that low concentrations of PVA added to the freezing mixture prior to 
cryopreservation decreased the overall concentrations of glycerol or DMSO required; therefore, 
with the implementation of PVA as a part of the freezing process, there is potential for decreased 
mechanical injury from ice crystal formation as well as decreased toxic effects resulting from 
CPAs, leading to any possible increases in recovery. 
Chapter 3: Experimental Methods 
3.1 Materials 
Primary Bladder Epithelial Cells (BdECs), Prostate Epithelial Cell basal media and 
Prostate Epithelial Cell growth kit were purchased from ATCC. BdECs obtained (Passage 2 - P2) 
were passaged (Passage 3 – P3) and stored in Liquid Nitrogen (LN2) in Cryovials (10
6/vial) with 
10% DMSO used as a cryoprotectant. The basal media and the growth kit were mixed together 
(referred to as complete media) and used as a growth medium for BdECs; the complete media was 
serum-free. The frozen cells were later grown in tissue culture flasks (P4) and harvested for further 
experiments. Dulbecco’s Phosphate Buffer Saline (DPBS) was purchased form Millipore Sigma 
(USA). Trypsin (0.25%, 2.21 mM EDTA without Ca, Mg and Na bicarbonates with Phenol red), 
Plasma treated tissue culture flasks (75 cm2) as well as 96 well plates were obtained from Corning. 
Trypan Blue solution (0.4%) was obtained from Gibco (USA). Live/Dead Cell viability assay kit 
(for mammalian cells) was obtained from Biovision (USA). DMSO (≥ 99.9%, anhydrous grade), 
Betaine (≥ 99.0%, molecular biology grade), L-Proline (≥ 99.5%, molecular biology grade), 
Trehalose (≥ 98.5%, cell culture grade), Dextran (average molecular weight 35,000-40,000) and 
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Poly (vinyl alcohol) (80% hydrolyzed, average molecular weight 9,000-10,000) were obtained 
from Sigma-Aldrich (USA). Poly (ethylene glycol)-400 (PEG-400) (reagent grade) was purchased 
from Merck (USA) and glycerol (≥ 99.0%, molecular biology grade) was purchased from 
Invitrogen (USA). 
3.2 Cell culture 
P3 cells were thawed and seeded onto 75 cm2 tissue culture flasks (T75 flasks) at a density 
of 5000 cells/cm2 as recommended by the ATCC with 10 mL of complete media. The flask was 
kept inside the incubator at 37oC, 95% air and 5% CO2. The media was replaced with 10 mL fresh 
media 2 days after seeding following which it was renewed every alternate day. When the flasks 
were 80-90% confluent, they were trypsinized using Trypsin/EDTA followed by centrifugation to 
separate the supernatant and the remaining cell pellet was re-suspended in 1 mL of complete 
medium for further experiments. 
3.3 Harvesting and freezing of cells 
Confluent cells on tissue culture flasks were removed from the incubator and their surface 
was washed with spent media followed by treatment with 3 mL Trypsin and incubation for 5 min. 
The flask was tapped to detach the loosely attached cells. 5 mL complete media was added to the 
flask and the complete solution was aspirated out followed by washing with DPBS. The cell 
suspension was centrifuged and supernatant aspirated out to obtain only the cell pellet which was 
resuspended in 1 mL complete media. Cell in the suspension were counted using hemacytomter 
and Trypan Blue (0.4%, Gibco) (1:1 mixture of cell suspension and Trypan Blue) and the 
suspension was diluted to 1 mL per 2 million cells. CPAs were mixed with complete media to 
prepare the cryopreservation solution and 0.75 mL of the solution was added in 1 mL cryovials to 
which 0.25 mL of the cell suspension was added to make final volume to 1 mL, cell density to 0.5 
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million cells/cryovial and total CPA concentration to 10% (w/v or v/v). The cryovials were allowed 
to equilibrate for 15 minutes following which they were transferred freezing. Multiple methods 
were used for freezing the cells, the description of which is given in later sections. 
Table 1. 
Cryoprotective agent-medium mixture composition. 
 
3.4 Thawing and reseeding of cells 
The cryovials were removed from the liquid N2 tank and kept in a bead bath for 5 minutes 
(ice pellet completely disappeared by that time). The solution in each cryovial was transferred in 
5 mL complete media and centrifuged at 1000 rpm for 5 min. After centrifugation, the supernatant 
was aspirated out and the pellet was resuspended in 5 mL complete media followed by 
centrifugation at 1000 rpm for 5 min. After aspirating out the supernatant and resuspending the 
pellet in 1 mL media, the cells were counted using hemocytometer. Appropriate number of cells 




3.5 Cell counting for post thaw recovery test 
20 μL of the cell suspension was mixed with 80 μL of hBEC media as well as 100 µL of 
Trypan blue and injected into the hemocytometer. The average of the four squares was multiplied 
by a factor of 105 to account for the dilution in order to obtain the final cell count. The counting 
process was repeated three times per vial frozen, to minimize error.  
3.6 Viability of cells for observation of cell proliferation 
Viable cells are counted using Live/Dead Assay kit and EVOS FLAuto 2 microscope under 
GFP (for live cells) and RFP (for dead cells) filter. The staining solution is prepared in accordance 
with the protocol mentioned on the website. One-hundred μL of the spent media is removed from 
all the wells to be analyzed followed by addition of 25 μL of the staining solution in each well. 
The wells are imaged under the microscope after gentle mixing followed by an incubation period 
of 15 min. The images obtained are processed with ImageJ to obtain the cell count. The counting 
method is validated by visually counting the cells in some wells and comparing with the results 
generated from ImageJ. A macro was then developed to automate the validated image processing 
method and used to analyze all the images. 
3.7 Statistics 
Three samples were used to obtain the mean and standard deviation for each data point. To 
compare the data between multiple groups, a two-way ANOVA test was used; otherwise, for 
comparisons against a positive control, a one-way ANOVA test was used. Data were considered 




Chapter 4: Results 
Chemical composition of freezing solution 
4.1 Screening of penetrating and non-penetrating CPAs for recovery and initial viability 
Due to the limited understanding of the cryopreservation of hBECS, CPAs were selected 
based on prior cryopreservation research performed on different cell lines, as well as what has 
been previously seen in nature. To test the most appropriate CPA, hBECs were treated with a 
freezing solution of which the CPA concentration was consistently 10% (w/v or v/v), or with no 
CPA. hBECs were cryopreserved for seven days prior to thawing, and initial cell recovery was 
measured immediately after thawing using a hemocytometer and trypan blue staining. As shown 
in Figure 1, no significant difference in cell viability was observed between DMSO, PEG, and 
trehalose. However, the recovery of hBECs that were treated with glycerol, betaine, L-proline, and 
dextran were comparable to one another, and significantly lower than those treated with DMSO, 
PEG, and trehalose.  
The number of viable cells was significantly lower in samples treated with glycerol, 
betaine, L-proline, and dextran compared to that of cells treated with DMSO, PEG, or trehalose. 
While the number of viable cells was slightly lower when treating cells with trehalose compared 
to DMSO and PEG it still performed significantly better than the majority of the CPAs. Based on 
the results of initial recovery, DMSO would be the standard pCPA that would be tested in further 
experiments; in addition, PEG and trehalose would be selected as the npCPAs that would be tested 





Table 2.  
Post-thawing recovery cell count per milliliter. 
 
 
Figure 1. hBEC initial post thaw recovery after cryopreservation with different CPAs. Eight cryovials containing 0.5 
x 106 hBECs were each frozen with a different CPA. The figure above is a graphical representation of the number of 
cells recovered immediately after thawing from cryopreservation for seven days at -140oC. ***p < 0.001 and ****p 




4.2 Screening of penetrating and non-penetrating CPAs based on cell growth 
Because trypan blue staining only provided a measure of initial viability, proliferation and 
continued viability was measured using live/dead staining and an EVOS FLAuto 2 microscope. 
hBEC viability was assessed by the amount of time that was required for hBECs to reach 
confluency. Two days after seeding in the 96 well plate, cells treated with DMSO, dextran, and no 
CPA displayed recoveries lower than cells treated with other types of CPAs. hBECs treated with 
glycerol, on the other hand, while initially showing limited recovery immediately after thawing, 
resulted in significant growth two days after seeding and frequently showed the significant growth 
throughout the eight-day growth period. DMSO, on the other hand, showed the greatest initial 
viability among the pCPAs, but resulted in significantly less proliferation compared to glycerol 
and L-proline. However, by the eighth day, DMSO and trehalose showed the greatest proliferation 
among the CPAs. It was also observed that hBECs treated with pCPAs showed the greatest 
percentage in growth between the fourth and fifth day after seeding, while hBECs treated with 
npCPAs showed the greatest growth between the sixth and eighth day after seeding. 
From these data, we concluded that, based on proliferation data, the two best performing 
pCPAs were DMSO and glycerol. As shown in Figure 1 and 3, hBECs treated with DMSO resulted 
in both the highest recovery immediately after thawing and the greatest overall proliferation after 
the eight-day growth period. Cells treated with glycerol, on the other hand, frequently showed 
significant growth during the period, with an overall cell count similar to DMSO. Among the 
npCPAs, PEG and trehalose were the best performing for the hBECs; while cells treated PEG 
resulted in a higher immediate post-thawing recovery, cells treated with trehalose resulted in 




Figure 2. hBEC growth at two (A), four (B), six (C) and eight (D) days. Cells were treated with (i) DMSO, (ii) 
glycerol, (iii) PEG, (iv) trehalose, or (v) no CPA and seeded in a 96 well plate and imaged at 4x magnification with a 




Figure 3. Growth of hBECs cryopreserved with various CPAs over an 8-day period. hBECs were resuspended and 
cryopreserved with either A) pCPAs or B) npCPAs Cells were seeded in 96 well plates at a density of 5000 cells/cm2 
and imaged two days after seeding to allow for adhesion and growth on the surface. hBECs were imaged at 4x 




4.3 Effect of CPA mixtures on recovery 
 Previous research has shown that cells treated with a freezing mixture of containing both 
penetrating and non-penetrating CPAs resulted in higher recoveries than if the cells were treated 
with one or the other. Therefore, we took the results of the previous experiment to determine the 
appropriate CPA mixture solution as the best performing ratio. We determined that among the 
pCPAs, DMSO was the best performing due to a high initial post thaw recovery and greatest 
overall growth. Among the npCPAs, trehalose and PEG performed comparably when measuring 
initial post thaw recovery and proliferation, with cells treated with trehalose resulting in greater 
recovery; however, upon further testing, we found that cells treated with trehalose tended to be 
contaminated, possibly due to trehalose being a sugar that may easily allow for bacteria to grow. 
Therefore, the npCPA selected to proceed with the CPA mixture experiments was PEG.  
 hBEcs were treated with a mixture of DMSO and PEG in varying concentrations, both the 
overall concentration of CPA in each vial remained to be 10% v/v. Cells were harvested and 
aliquoted into cryovials, with respective amounts of DMSO + PEG shown in Table 3.  
Table 3.  
Combinations of DMSO and PEG in varying amounts. 
 
 Cells were frozen for 3 days, and then initial post-thaw recovery was measured using a 
hemocytometer and trypan blue staining.  
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Figure 4. Initial recovery of hBECs following cryopreservation comprising of DMSO and PEG mixtures. The total 
amount of CPA remained to be 10% v/v; however, the amount of DMSO varied from 0%, 2.5%, 5.0%, 7.5%, and 
10% DMSO, with PEG composing the remaining 10%, 7.5%, 5.0%, 2.5%, and 0%, respectively, for 7 days at -140oC. 
p > 0.05 compared to samples frozen with 10% DMSO.  
 
While cells treated with the CPA mixture comprising of 5.0% DMSO and 5.0% PEG 
resulted in the highest post-thaw recovery, the increase was insignificant. The post thaw recoveries 
of hBECs treated with 10% DMSO and 0% DMSO (10% PEG) were consistent with that of Figure 
1, and hBECs that were treated with 2.5% DMSO + 7.5% PEG as well as 7.5% DMSO + 2.5% 
PEG were only slightly higher. Based on the results, we determined that 10% DMSO or 10% PEG 
was still a suitable CPA solution for a recovery of 70%; any increases in recovery can be obtained 
due to mixing of the two CPAs.  
4.4 Effect of ROCK Inhibitor on recovery 
 Previous research has shown that the incorporation of ROCK inhibitor in stem cell 
cryopreservation was shown to increase the recovery as well as proliferation. As part of a previous 
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protocol regarding the cryopreservation of stem cells, ROCK inhibitor was included into the 
freezing media prior to freezing, as well as into the culturing medium after thawing. Therefore, a 
1000 μM solution of ROCK inhibitor in hBEC media was developed and filtered via vacuum 
filtration. The ROCK inhibitor solution was then further diluted into 100 μM, 50 μM, 10 μM, 5 
μM, and 1 μM, and each dilution was added into the freezing medium containing 10% DMSO. 
Samples were frozen for 7 days at -140oC and thawed at 37oC; recovery was determined via 
hemocytometer and trypan blue staining.  





















Figure 5. Initial post thaw recovery of cells treated with ROCK inhibitor and 10% DMSO. ROCK inhibitor was 
incorporated into hBEC suspensions at varying concentrations and samples were frozen for 7 days at -140oC. Post 
thaw recovery was obtained via hemocytometer and trypan blue staining after thawing at 37oC. *p < 0.05 and **p < 
0.01 for samples treated with no ROCK inhibitor and 10% DMSO.  
 
It was found that samples treated with 10 μM prior to freezing resulted in the greatest 
overall recovery. As shown in Figure 5, while there was an increase in recovery with the addition 
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of ROCK inhibitor, it appeared that was an optimal concentration that would result in the greatest 
recovery. Changes were insignificant when 50 μM and 100 μM was incorporated into the freezing 
mixture, and was found to actually significantly decrease recovery when adding 1000 μM.  
4.5 Effect of IRIs on recovery 
It has been previously researched that the addition of PVA has inhibitory effects on ice 
nucleation. As an ice recrystallization inhibitor, PVA can adsorb to the surface of ice crystals 
which can preemptively prevent any mechanical injury that results from additional ice crystal 
growth. A stock solution of 8 μM PVA in hBEC culture medium was developed and filtered by 
vacuum filtration. The stock solution was further diluted accordingly into 4 μM, 2 μM, 1 μM, and 
0.5 μM, which was then added into the cell suspension mixture with CPA prior to freezing. The 
effects of PVA on hBECs’ post-thawing recovery were measured after 7 days of cryopreservation.  






















Figure 6. Initial recovery of hBECs treated with PVA in addition to 10% DMSO. Samples were evaluated for recovery 
via hemocytometer and trypan blue after being cryopreserved for 7 days and immediately thawing at 37oC. ***p < 




It was found that hBECs treated with 10% DMSO with 1 μM of PVA had a recovery that 
was significantly greater than the samples treated with PVA, including the control sample that was 
did not contain PVA in the freezing mixture. In addition, as shown in Figure 5, the addition of 1 
μM to the freezing mixture was the optimal concentration, as additions of 0.5 μM and 2 μM PVA 
seemed to have an insignificant effect on the recovery, while greater concentrations of 4 μM 
actually resulted in a significant decrease in recovery.  
 
Physical parameters of freezing 
4.6 Effect of cooling rates on recovery 
Previous research has shown that the rate of freezing has a pronounced effect on the 
recovery of cells. Typically, mammalian cells are frozen at a rate between -1o to -2oC, but it has 
been found that different cell lines tolerate have optimal cooling rates. Therefore, we investigated 
different cooling rates and temperatures while using DMSO as the primary CPA. While we did 
not have a programmable controlled-rate freezer, we determined that samples are commonly 
frozen at in a -80oC freezer, or stored in a liquid nitrogen container; within the liquid nitrogen 
container itself, samples stored towards the top are exposed to vaporous nitrogen at -140oC, while 
samples stored towards the bottom are exposed to liquid nitrogen at -196oC. In addition, common 
lab practices include moving the samples to colder temperatures for long-term storage. Therefore, 







hBEC freezing conditions and their respective durations. 
 
 
Figure 7. hBECs were aliquoted into cryovials at a density of 0.5 x 106 cells/mL containing 10% DMSO and moved 
into different freezing conditions. hBECs were either kept in their respective freezers or moved after 24 hours into a 
different temperature. After 7 days total of cryopreservation, post-thaw recovery was obtained via hemocytometer and 
trypan blue staining. *p < 0.05 and ***p < 0.001 for samples frozen at -140oC, the current standard.  
 
As shown in Figure 7, hBECs frozen at -140oC were 150% times greater than those that 
were moved from -80oC to -140oC, and almost 300% times greater than those that were moved 
from -80oC to -140oC and finally -196oC. However, hBECs that remained at -80oC and those that 
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were moved from -140oC (vaporous N2) to -196
oC (liquid N2) had recoveries comparable to the 
original freezing condition, which was to freeze the cells at -140oC; hBECs that were moved from 
vaporous N2 to liquid N2 did increase in recovery, but only slightly, and hBECs that remained at -
80oC resulted in a slightly lower recovery. 
4.7 Effect of cell density on recovery 
In a protocol described by Freshney, hBECs were typically frozen at a cell density of 2.0 
x 106 cells/mL24; however, with the inconsistent recovery and quantities of cells after 
cryopreservation, the possibility of losing a large number of cells becomes very likely. Therefore, 
the majority of our experiments have been performed using a cell density of 0.5 x 106 cells/mL. 
On the other hand, the cell density may have some impact in cell freezing, potentially due to the 
space in between cells that may affect ice formation. We varied the cell density as shown in Figure 
8 and treated the samples with 10% DMSO, which were kept at -140oC for 7 days.  





















Figure 8. Initial post-thaw recovery of hBECs varying the cell density prior to freezing. hBECs were aliquoted into 
cryovials at different cell densities and treated with 10% DMSO. Samples were frozen at -140oC for 7 days, and post 
thaw recovery was obtained using hemocytometer and trypan blue staining. p > 0.05 compared to samples that are 
frozen at a cell density of 0.5 x 106 cells/mL.  
 
As shown in Figure 8, cell density did not have any significant effect on the post thaw 
recovery. While there was a slight increase in recovery when freezing at a density of 0.5 x 106 
cells/mL, there is no definitive advantage of freezing at one cell density over another. Therefore, 
the standard of freezing cells at a density of 0.5 x 106 cells/mL can still be implemented, but 
changes in cell density can ultimately be implemented with no detrimental effects to the recovery.  
 
4.8 Effect of equilibration time on recovery 
Immediately after the addition of CPAs, cells need to remain at room temperature for a 
certain amount of time to allow for the CPA to penetrate through the cell membrane, which we 
have deemed the “equilibration time”. Therefore, the equilibration time is only applicable to 
pCPAs, which exhibit cryoprotective properties by permeating through the cell membrane to 
prevent intracellular ice formation and dehydration. We varied the amount of time that we exposed 
the hBECs to DMSO at room temperature prior to freezing. In prior experiments, we have been 
exposing the hBECs to equilibrate at room temperature for 15 minutes.  
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Figure 9. Initial post-thaw recovery of hBECs with varying equilibration times. hBEC suspensions were aliquoted 
into cryovials at a cell density of 0.5 x 106 cells/mL and treated with 10% DMSO. Immediately after addition of 
DMSO, samples remained at room temperature either 5, 10, 15, or 20 minutes, and were frozen at -140oC. Post thaw 
recovery was obtained by hemocytometer and trypan blue staining. *p < 0.05 and **p < 0.01 compared to samples 
that remained at room temperature for 15 minutes after CPA addition. 
 
The equilibration time had a pronounced effect on the post thaw recovery of the hBECs. 
Samples that remained at room temperature for 5 minutes were significantly greater than those that 
remained at room temperature for 15 minutes. In addition, any increases in equilibration time 
resulted in significant decreases in recovery.  
Chapter 5: Discussion 
In tissue reconstruction of the bladder, hBECs are highly important in the development of 
the urothelium. Currently, hBECs are known to have a low recovery after cryopreservation and an 
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inconsistent growth, which proves to be experimentally problematic. While the cryopreservation 
of other epithelial cells has been optimized, effective cryopreservation of hBECs has not been 
thoroughly investigated as such. Ensuring for the greater recovery and shorter proliferation time 
to confluency allows for a more holistic understanding of the development of an engineered 
bladder, as well as providing insight to more effectively freeze bladder cells.  
In our research, we froze hBECs while altering one of two factors: the chemical 
composition of the freezing solution and the physical parameters involved with freezing. For each 
experiment performed, we found the initial recovery of the cells immediately after thawing using 
a hemocytometer and trypan blue staining; for experiments that looked at proliferation, we seeded 
hBECs into 96 well plates in which we monitored their growth over an eight-day period. Initially, 
we tested seven different CPAs of both the penetrating and non-penetrating variety. From both 
post-thaw recovery and proliferation experiments, we concluded that DMSO and PEG resulted in 
the greatest recoveries of cells as well as the greatest growth of cells after an eight-day growth 
period. These results build on existing evidence of the protocol described by Freshney, such that 
treating hBECs with DMSO resulted in a recovery of >70% after cryopreservation24. However, 
our results also indicate that PEG is a suitable CPA alternative for hBECs that produces similar 
results without the known toxicity issues from DMSO. The use of PEG as a CPA may also have 
clinical implications when reconstructing the urothelium, such that trace amounts will have less 
severe of an effect compared to using DMSO as a CPA, which has been known to have issues with 
cell signaling15. 
It has also been previously reported that a mixture of pCPAs and npCPAs enhances 
recovery of cells following cryopreservation due to the decreased cell volume and increased 
osmolarity, and previously shown that a CPA mixture with DMSO as the penetrating compound 
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enhanced recovery compared to DMSO by itself17,25,26. These reports are only somewhat consistent 
with our results, as shown in Figure 4; while the mixture between 5.0% DMSO and 5.0% PEG 
resulted in the greatest recovery of 87%, the increases are insignificant and the recoveries are 
ultimately comparable to that of 10% DMSO or 10% PEG. Upon initial review, these minor 
increases in recovery allow for the more complete usage of the samples frozen, but the original 
recovery from hBECs treated with 10% DMSO or 10% PEG is still sufficient and may not warrant 
the extra costs, resources, and effort involved in using PEG as an additive to the freezing mixture. 
On the other hand, however, it is also confirmed that freezing mixtures comprised of both DMSO 
and PEG result in comparable, if not higher recovery. These results are still relevant to any sort of 
clinical applications, such that in the cryopreservation of these cells, one could potentially offset 
the toxicity that stems from DMSO by reducing its amount required with the addition of DMSO. 
Previous studies have reported that dilute concentrations of ROCK inhibitor during 
culturing after cryopreservation has significantly increased the proliferation rate 18,27,28. In addition, 
a previous protocol regarding the cryopreservation of stem cells implemented ROCK inhibitor in 
the freezing mixture as well as into the culturing medium. With the addition of ROCK inhibitor in 
the freezing mixture, our results showed that cells treated with 10 μM of ROCK inhibitor resulted 
in the greatest recovery. These results build on existing evidence that shows that there is an optimal 
concentration of ROCK inhibitor at which the cells have a greater recovery or growth29. While 
these experiments were performed with the intention of increasing recovery instead of increasing 
the proliferation rate, the methodological choices were constrained by the lack of consistent 
quantities and quality of hBECs when experimenting with ROCK inhibitor in the culturing 
medium. However, incorporation of ROCK inhibitor in the freezing medium did result in a 
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significant recovery, which may be investigated as a contributing factor in future experiments 
when investigating proliferation. 
The results also indicate that the addition of PVA also had a profound effect on the recovery 
of the hBECs. As shown in Figure 6, cells treated with an optimal concentration of 1 μM PVA 
resulted in the greatest recovery of 76%, significantly higher than those that were untreated with 
PVA; in addition, too high of a concentration resulted in a significant decrease in the recovery 
following cryopreservation. These results are in line with the previous studies, which suggested 
that dilute amounts of PVA would allow for greater recovery22,23.These results build on existing 
evidence that addition of PVA allows for the increase in recovery; the increases in recovery may 
be a result of a combination of the decreased toxic effects of DMSO, as well as the decreased 
mechanical injury that results from intracellular ice formation. 
In terms of the physical parameters, we found that the equilibration time had a profound 
impact on the recovery of cells. Previously, after the addition of CPA, we let the cells remain at 
room temperature for 15 minutes; while this equilibration time would only apply to pCPAs, the 
results indicate that increases in equilibration time resulted in a decrease in recovery. While there 
has not been previous research done on the exact phenomenon, DMSO is known to be toxic to 
cells, and prolonged exposure to DMSO at room temperature would result in a decrease in recovery 
or viability. Therefore, an equilibration time of 5 minutes is a sufficient amount of time for DMSO 
to exhibit its cryoprotective effects as well as ensuring a higher recovery. In other previous 
research, the cooling rate and freezing temperature has also been a major factor in the survivability 
of cryopreserved cells. Previous research has found that there is an optimal rate at which cells are 
cryopreserved, which may vary among different cell lines16,30,31. While these reports may not 
immediately correlate with our findings of an optimal cooling rate or freezing temperature, our 
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data does imply that the cooling rate and duration spent at different temperatures has a pronounced 
effect on the post thaw recovery. hBECs that were moved from -80oC to N2 storage resulted in the 
lowest recoveries among the freezing conditions, potentially due to a steep decrease in temperature 
rather than a gradual decrease that can be obtained through a controlled rate freezer. The low 
recovery in the hBECs that were moved from -80oC may have also resulted from any thawing that 
may have occurred in between transferring among different freezers; this result can also be 
supported by hBECs that were moved from vaporous N2 to liquid N2, as they may have had 
minimal exposure to external temperatures30,31.  
However, despite the consistency in higher recovery, our results cannot conclude whether 
the hBECs exhibited their specific markers and would have been able to function as a component 
of the urothelium. As mentioned previously, in many of our experiments following the initial 
screening of CPAs, we consistently found that hBECs that were seeded into 96 well plates for 
proliferation studies were inconsistent in their growth and degree of contamination, thereby giving 
us inconclusive data regarding the effect of CPA mixtures and ROCK inhibitor on the proliferation. 
In addition, the lack of a controlled rate freezer may have created some limitations in the study; a 
programmable cooling rate can be set to be constant for all conditions that were being tested, which 
could potentially exclude it as a factor that may have caused any discrepancies. A programmable 
cooling rate also allows for the possibility that an optimal cooling rate34 that is the most suitable 
for hBECs.  
Despite these limitations, each of the experiments provided insight as a method to 
potentially increase recovery immediately after thawing, as shown by the significant increases after 
treatment. Based on these data, further research is required to investigate long term viability of 
these cells, as well as the effects of cryopreservation on urothelial marker expression. Possible 
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future directions include the use of Raman spectroscopy to observe the cell morphology during 
freezing. In addition, other future directions include observing the sustainability and viability of 
hBECs in clinical applications, specifically to research the effects of different chemical 
compositions and freezing rates in vivo, and to eventually implement these cryopreserved cells in 
tissue regeneration.  
We can therefore conclude that DMSO and PEG, perform comparably in terms of their 
cryoprotective capabilities, and treatment with mixtures of the two CPAs can also provide 
consistent recoveries. Addition of an optimal concentration of ROCK inhibitor or PVA prior to 
freezing also resulted in significantly higher recoveries. In terms of physical parameters, increases 
in time spent at room temperature following the addition of the freezing mixture will result in a 
decrease in recovery. Based on these data, we have developed a method that can successfully allow 
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